Table 5 Specific adverse events (treatment related) in comparisons with placebo
From: Sildenafil (Viagra) for male erectile dysfunction: a meta-analysis of clinical trial reports
| Â | Â | Â | Number (%) with outcome | Â | ||
|---|---|---|---|---|---|---|
Dosing (mg) | Number of trials | Adverse event | Sildenafil | Placebo | Relative risk (95% CI) | NNH (95% CI) |
25 | 3 | Dyspepsia | 4/312 (1.2) | 1/426 (0.2) | 4.4 (0.6 to 34) | |
| Â | Â | Headache | 31/312 (10) | 14/426 (3.2) | 3.1 (1.6 to 6.1) | 15 (9.6 to 34) |
| Â | Â | Vasodilation | 30/312 (9.6) | 4/426 (1.0) | 11 (3.8 to 29) | 12 (8.3 to 19) |
50 | 5 | Dyspepsia | 24/511 (4.7) | 4/607 (0.7) | 6.4 (2.4 to 17) | 24 (17 to 47) |
| Â | Â | Headache | 77/511 (15) | 21/607 (0.3) | 4.5 (2.8 to 7.3) | 8.6 (6.6 to 12) |
| Â | Â | Vasodilation | 94/511 (18) | 11/607 (1.8) | 9.7 (5.4 to 18) | 6.0 (5.0 to 7.7) |
100 | 5 | Dyspepsia | 60/506 (12) | 4/607 (0.7) | 15 (5.8 to 40) | 8.9 (7.1 to 12) |
| Â | Â | Headache | 115/506 (23) | 21/607 (0.3) | 6.8 (4.3 to 11) | 5.2 (4.3 to 6.5) |
| Â | Â | Vasodilation | 90/506 (17) | 11/607 (1.8) | 9.2 (5.0 to 17) | 6.3 (5.1 to 8.0) |
200 | 2 | Dyspepsia | 35/191 (18) | 3/181 (1.7) | 11 (3.5 to 35) | 6.0 (4.5 to 9.2) |
| Â | Â | Headache | 62/191 (32) | 7/181 (3.9) | 8.4 (4.0 to 18) | 3.5 (2.8 to 4.7) |
| Â | Â | Vasodilation | 43/191 (22) | 7/181 (3.9) | 5.9 (2.7 to 13) | 5.4 (4.0 to 8.3) |
Dose optimised | 5 | Dyspepsia | 24/517 (4.6) | 7/524 (1.3) | 3.4 (1.5 to 7.9) | 31 (19 to 82) |
| Â | Â | Headache | 63/517 (12) | 10/524 (1.9) | 6.3 (3.2 to 12) | 9.8 (7.5 to 14) |
| Â | Â | Vasodilation | 65/517 (13) | 4/524 (0.8) | 16 (6.0 to 44) | 8.5 (6.7 to 11) |